Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry
Fig 4
Proposed metabolic pathways of gefitinib in humans in vivo.
Compound marked with dotted bracket is given to elucidate the proposed metabolic pathways, which were not observed.